Ian W. Flinn

Medicine · Health Sciences

94h-index53.8kcitations927works4.92yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(592), Lymphoma Diagnosis and Treatment(494), CAR-T cell therapy research(169), Chronic Myeloid Leukemia Treatments(122), Immunodeficiency and Autoimmune Disorders(103)

Publications927 total

Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis
Figshare·2026Open Access
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis
Figshare·2026Open Access
Supplementary Figure S1 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Data from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S8 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Methods S1 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Tables S1-S10 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S5 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S9 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S6 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S3 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S7 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S10 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S2 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S4 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Data Tables from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
2025Open Access
Supplementary Data Figures from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
2025Open Access
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis
Current Medical Research and Opinion·2025
Supplementary Table S3 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
2025Open Access
Supplementary Data 1 from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
2025Open Access
page 1 of 47Next →

Frequent Co-authors

John C. Byrd(9), Steven Coutré(8), John M. Pagel(8), Nancy L. Bartlett(7), Paolo Ghia(7), Brad S. Kahl(7), Frederick L. Locke(6), Caron A. Jacobson(6), André Goy(6), Peter A. McSweeney(6), Javier Muñoz(6), Patrick M. Reagan(6), Richard R. Furman(6), Jeff P. Sharman(6), Hagop M. Kantarjian(6), Richard A. Larson(6), Franck Morschhauser(6), David B. Miklos(5), John M. Timmerman(5), Brian T. Hill(5)